How would you structure the follow-up interval – both in terms of timing and content – for a low-risk leukemic mantle cell lymphoma (no TP53 mutation), with 5% mantle cell lymphoma cells detected in both peripheral blood and bone marrow, mild splenomegaly (13 cm), and no lymphadenopathy or B symptoms?